Overview

XIENCE 28 Global Study

Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting Coronary Stent System [EECSS], XIENCE Alpine EECSS, XIENCE PROX EECSS, XIENCE ProA EECSS or XIENCE Sierra EECSS of coronary drug-eluting stents
Phase:
N/A
Details
Lead Sponsor:
Abbott Medical Devices
Abbott Vascular